Lee, M. H., McCall, W., Cwykiel, J., Lin, C., Madarang, E., Watts, J. M., … Fathi, A. T. (2024). Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction. In Blood (Vol. 144, pp. 4282–4282). American Society of Hematology. https://doi.org/10.1182/blood-2024-205931

Lee, Michelle Hyunju, Wyatt McCall, Joanna Cwykiel, Chenyu Lin, Ellen Madarang, Justin M. Watts, Harry P. Erba, et al. “Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction.” In Blood, 144:4282–4282. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-205931.

Lee MH, McCall W, Cwykiel J, Lin C, Madarang E, Watts JM, et al. Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction. In: Blood. American Society of Hematology; 2024. p. 4282–4282.

Lee, Michelle Hyunju, et al. “Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 4282–4282. Crossref, doi:10.1182/blood-2024-205931.

Lee MH, McCall W, Cwykiel J, Lin C, Madarang E, Watts JM, Erba HP, Abaza Y, Perl AE, Matthews AH, Brunner AM, Fathi AT. Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction. Blood. American Society of Hematology; 2024. p. 4282–4282.